论文部分内容阅读
由于发现美国许多血友病患者因接受未经加热处理的凝血因子浓制剂而接触人类免疫缺陷症病毒(HIV),因此加热处理的凝血因子浓制剂应运而生。有一些美国以外的血友病治疗中心(HTC)使用加热处理制剂早于美国,最近,其中1个主要的HTC的血标本发现使用加热处理凝血因子制剂发生了HIV血清阳转,因而要求美国国家血友病基全会帮助估价他们的患者发生血清阳转的危险性。资料来自西欧、加拿大和澳大利亚的13个HTC,内容包括他们患者的HIV抗体阳性
As a result of the discovery that many hemophiliacs in the United States are exposed to human immunodeficiency virus (HIV) as a result of receiving non-heat-treated coagulation factor concentrates, heat-treated coagulation factor concentrates have emerged. Some Hemophilia Treatment Centers (HTC) outside the United States used heat-treatment preparations earlier than the United States. Recently, one of the major HTC blood samples found that HIV seroconversion occurred using heat-treated coagulation factor preparations, Hemophilia Plenary helps to gauge the risk of seroconversion in their patients. Data from 13 HTC in Western Europe, Canada and Australia included HIV-positive patients in their patients